Of note, among the recurrent oncogenic mutations identified in HCC, the most prevalent is telomerase reverse transcriptase (TERT) promoter (TERTp) mutations, which occurs in up to 60% of patients, highlighting the importance of telomere biology in HCC molecular pathogenesis 4. Here, TERT is linked to hepatocellular carcinoma.